
BGB-43395 Plus Letrozole versus CDK4/6i Plus Letrozole for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease (BeOne/KANDELA-302)
Short Title: BGB-43395
Enrollment Status: Recruiting
NCT #: NCT07492641
Specialty Area: Oncology
Condition Studied: Advanced or Metastatic HR+/HER2- Breast Cancer
Age Groups: Adult; Older Adult
Study Information
Summary / Purpose
To compare the effectiveness and safety of BGB-43395 in combination with letrozole or an investigator-selected approved CDK4/6 inhibitor for adults with advanced or metastatic HR-positive/HER2-negative breast cancer who have not previously received systemic anticancer treatment for advanced or metastatic disease.
Who Can Participate
- Adults 18+ years of age
- Confirmed HR-positive/HER2-negative advanced or metastatic breast cancer
- No prior systemic anticancer treatment for advanced or metastatic disease
- Must have an ECOG performance status of 0–1 and either measurable disease by RECIST v1.1 or evaluable bone disease
- Visceral metastases may be eligible, but those with visceral crisis are excluded
What's Involved
- Random assignment to receive either BGB-43395 plus letrozole or an investigator-selected CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) plus letrozole.
- Attending regular clinic visits
- Tumor imaging, laboratory testing, and safety assessments to monitor treatment response and side effects
Principal Investigator

Additional Information
Address: 1500 E 2nd St. Reno, NV 89502
General Research: 775-982-3646
Oncology Research: 775-982-5050
Email: Renown-CRD@renown.org
Complete Study Details: https://clinicaltrials.gov/study/NCT07492641
Disclaimer: This listing gives you general information about the study and isn't part of the official consent process. If you decide to learn more, the research team will talk with you and check if you meet any additional requirements to join the study.